These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 11238512)

  • 1. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults.
    Laursen T; Gravholt CH; Heickendorff L; Drustrup J; Kappelgaard AM; Jørgensen JO; Christiansen JS
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1222-8. PubMed ID: 11238512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
    Laursen T; Jørgensen JO; Jakobsen G; Hansen BL; Christiansen JS
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: I. Effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis.
    Johansson JO; Oscarsson J; Bjarnason R; Bengtsson BA
    Metabolism; 1996 Mar; 45(3):362-9. PubMed ID: 8606645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
    Thorén M; Hilding A; Baxter RC; Degerblad M; Wivall-Helleryd IL; Hall K
    J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of the 150-kilodalton insulin-like growth factor-binding protein-3 ternary complex by continuous and pulsatile patterns of growth hormone (GH) administration in GH-deficient patients.
    Laursen T; Flyvbjerg A; Jørgensen JO; Baxter RC; Christiansen JS
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4310-4. PubMed ID: 11095473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone (GH) replacement in GH-deficient adults: a crossover trial comparing the effect on metabolic control, well-being and compliance of three injections per week versus daily injections.
    Johansson JO; Wirén L; Oscarsson J; Bengtsson BA; Johannsson G
    Growth Horm IGF Res; 2003 Dec; 13(6):306-15. PubMed ID: 14624763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
    Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults.
    Laursen T; Jørgensen JO; Christiansen JS
    Clin Endocrinol (Oxf); 1994 Sep; 41(3):337-43. PubMed ID: 7525120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)-treated GH-deficient patients.
    Laursen T; Møller J; Fisker S; Jorgensen JO; Christiansen JS
    Growth Horm IGF Res; 1999 Dec; 9(6):451-7. PubMed ID: 10629166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency.
    Gill MS; Toogood AA; Jones J; Clayton PE; Shalet SM
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1288-95. PubMed ID: 10199769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persisting effects on fasting glucose levels and insulin sensitivity after 6 months of discontinuation of a very low-dose GH therapy in adults with severe GH deficiency.
    Yuen KC; Dunger DB
    Clin Endocrinol (Oxf); 2006 May; 64(5):549-55. PubMed ID: 16649975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices.
    Jørgensen JO; Møller N; Lauritzen T; Christiansen JS
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1616-23. PubMed ID: 2189886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body composition and circulating levels of insulin, insulin-like growth factor-binding protein-1 and growth hormone (GH)-binding protein affect the pharmacokinetics of GH in adults independently of age.
    Hansen TK; Jørgensen JO; Christiansen JS
    J Clin Endocrinol Metab; 2002 May; 87(5):2185-93. PubMed ID: 11994362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: serum levels and hepatic messenger ribonucleic acid responses in humans.
    Olivecrona H; Hilding A; Ekström C; Barle H; Nyberg B; Möller C; Delhanty PJ; Baxter RC; Angelin B; Ekström TJ; Tally M
    J Clin Endocrinol Metab; 1999 Feb; 84(2):553-60. PubMed ID: 10022415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration.
    Laursen T; Grandjean B; Jørgensen JO; Christiansen JS
    Eur J Endocrinol; 1996 Sep; 135(3):309-15. PubMed ID: 8890721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency.
    Yuen KC; Frystyk J; White DK; Twickler TB; Koppeschaar HP; Harris PE; Fryklund L; Murgatroyd PR; Dunger DB
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):428-36. PubMed ID: 16181235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients.
    Laursen T; Møller J; Jørgensen JO; Orskov H; Christiansen JS
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):333-9. PubMed ID: 8949572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.